http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103204838-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2012-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103204838-B |
| titleOfInvention | The synthesis of polyhydroxy Benzofurantone compound and its antitumor action |
| abstract | There is formula there is provided a class In some embodiments of the present invention（I）The polyhydroxy Benzofurantone compound and its pharmaceutically acceptable salt or prodrug of structure, and the pharmaceutical composition containing such compound, they can be used to regulate and control the function of new estrogenic acceptor ER α 36, prevention and/or treatment are by the receptor-mediated related neoplasms diseases of ER α 36, such as breast cancer, leukaemia, liver cancer etc.. |
| priorityDate | 2012-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.